pre-IPO PHARMA

COMPANY OVERVIEW

Cell Medica is committed to improving patients’ lives through the significant therapeutic potential of cellular immunotherapy. Their approach is to apply innovative technologies with the aim of improving the treatment of cancer and immune reconstitution following hematopoietic stem cell transplant.


LOCATION

  • London, , UK
  • Houston, TX, USA
  • Schlieren, Zurich, Switzerland

  • THERAPEUTIC AREAS


    WEBSITE

    https://cellmedica.com/


    CAREER WEBSITE

    https://cellmedica.com/careers/


    SOCIAL MEDIA


    INVESTORS

    ip-group


    PRESS RELEASES


    Jan 21, 2021

    Kuur Therapeutics Announces Interim Clinical Data Supporting CAR-NKT Cell Therapy Platform


    Oct 12, 2020

    Kuur Therapeutics Announces Publication of Interim Phase 1 Data for CAR-NKT Cell Therapy KUR-501 in Nature Medicine


    Sep 29, 2020

    Kuur Therapeutics Announces First Patients Dosed with Allogeneic CAR-NKT Cell Therapy


    Mar 10, 2020

    Kuur Therapeutics Launches to Develop and Commercialize “Off-the-shelf” CAR-NKT Cell Therapies Targeting Hematological and Solid Tumors


    May 1, 2019

    Cell Medica Collaborators, Baylor College of Medicine and Texas Children’s Hospital, Present Preclinical Data for an off-the-shelf CAR-NKT Therapy Platform at American Society of Gene and Cell Therapy 22nd Annual Meeting


    For More Press Releases


    Google Analytics Alternative